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The synthesis of some new heterocyclic derivatives comprising imidazothaidiazole, diaryl ketone and chromen as 
starting compound has been reported. The new series of chromen analogues have been synthesized. The reaction has been 
monitored by Thin Layer Chromatography (TLC) using suitable mobile phase. The Rf values have been compared and the 
melting points of derivatives determined. Further, these derivatives have been characterized and confirmed by IR, 1H NMR 
and mass spectral (MS) studies. All the selected compounds submitted to National Cancer Institute (NCI) for in vitro 
anticancer assay have been evaluated for their anticancer activity. 
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Cancer is the second leading cause of death in the 
world. Now a days, chemotherapy, surgery, 
radiotherapy and endocrine therapy have been the 
standard treatment available for patients1-3. It is an 
urgent need to develop newer more effective 
therapies to improve patient outcome. In the present 
study we have reported the synthesis of some new 
heterocyclic derivatives comprising imidazothaidiazole, 
diaryl ketone and chromen as starting compound4-43. 
Chromen are of interest because of their diverse 
biological activities and clinical applications. We 
have reported the new series of chromen analogues to 
target HIF (Hypoxia Inducing Factor) inhibitors. The 
proposed molecule is structurally similar to the drug 
Seselin, which also inhibits the hypoxia inducible 
factor in anti cancer treatment (Figure 1). By using 
seselin, proposed molecule is modified and to 
synthesize the derivatives which have also gives 
potent anticancer activity. 
Material and methods 
For the synthesis of chromen derivatives the  
chemical are used 4-hydroxybenzaldehyde, 3-chloro-
3-methyl-1-butyne, DMF (Di methyl formamide),
NaOH, Ddiethyl ether, brine, NMP (N-Methyl-2-
pyrrolidone), magnesium sulphate, ethylacetate, N-
hexane, 2,2-dimethyl-2H-chromen-6-carbaldehyde,
thiosemicarbazide, ethanol, FeCl3, citric acid, sodium
citrate, ammonia, salisaldehyde, ethylacetoacetate, 
piperidine, KBr pellets. These all chemical are 
purchased from Alfa Asar, Rankem, Finar, 
Chemdynes, Chinachangshu yangyuan chemicals, 
Avra, Lobal chemie, Astron. 
The purity of the compound was confirmed by 
Thin Layer Chromatography using precoated TLC 
plates (MACHEREY-NAGEL SIL G/UV254), 
Melting points of synthesized compounds were 
performed in one end open capillary on Veego (VMP-
PM) melting point apparatus, Infrared (IR) were 
recorded for the synthesized compounds on Shimadzu 
Figure 1 — Design strategy of proposed molecule




FTIR-8400 (4000-400 ν max in cm-1) 
Spectrophotometer in KBr disc. Mass spectra  
(GC-MS) of synthesized compounds were performed 
on SHIMADZU QP-2010. 1H NMR spectra of 
synthesized compounds were recorded on Bruker 
AVANCE-III 400 MHz FT-NMR instrument by using 
DMSO-d6 as solvent, TMS (Tetra Methyl Silane) as 
internal standard and chemicals shifts in parts per 
million (ppm). 
 
Procedure for synthesis of 2, 2-dimethyl-2H-
chromen-6-carbaldehyde 
A solution of 4-hydroxybenzaldehyde (20 mmole) 
and 3-chloro-3-methyl-1-butyne (10 mmole) in 8 ml 
of DMF was taken in reaction flask. This solution was 
mixed with 5 ml (4 N) aqueous NaOH solution. The 
mixture was stirred vigorously at 60°C for 20 h. After 
cooling 20ml of water was added to the reaction 
mixture, which was extracted with 30ml of diethyl 
ether three times for consuming maximum product. 
The organic layer was washed with 40ml (1 N) 
aqueous NaOH Solution and brine. Then it was dried 
with magnesium sulphate. A pale yellow viscous 
liquid was produced as a crude product. A crude 
product was dissolved in 20ml of N-methyl-2-
pyrrolidone, NMP (BP 202°C) and then it was 
refluxed for 18 h. After cooling 40ml of water  
was extracted with 60ml diethyl ether three times  
for the desired conversion of maximum product.  
The combined organic layer was than washed  
with brine solution and also it was dried with 
magnesium sulphate. The product was recrystallised 
with n-hexane (Scheme I). 
 
Procedure for synthesis of 5-(2,2-dimethyl-2H-
chromen-6-yl)-1,3,4-thiadiazol-2-amine 
2,2-Dimethyl-2H-chromen-6-carbaldehyde (0.01mol) 
in ethanol 10ml is added into thiosemicarbazide 
(0.01mol) into 20ml hot ethanol over a period of 
10min with continuous stirring. The reaction mixture 
was reflux for 2 h and allows cooling where a shiny 
yellow compound began to separate. It was filtered 
and then washed with ethanol and then dried. The 
compound was recrystallized from hot ethanol, giving 
light yellow like crystals. Then Thiosemicarbazone VI 
(0.05M) was suspended in 300ml warm water, FeCl3 
(0.15M) in 300ml water was added quantitatively 
slowly with constant stirring. The contents were 
heated at 80-90°C for 45 min. This solution was hot 
filtered and then citric acid (0.11M) and sodium 
citrate (0.05M) were added. The resulting mixture 
was neutralized with ammonia (10%). The required 
amine separated out, filtered and dried. And also 
recrystallized with appropriate solvent (Scheme II). 
 
Procedure for synthesis of 2-bromo-2-(4-
fluorophenyl)-1-(4-methoxyphenyl) ethanone 
To a mixture of phenyl acetic acid/p-substituted 
phenyl acetic acid (7.3 mmol), substituted aromatic 
hydrocarbon (one of 8.8 mmol) and 88–93% 
orthophosphoric acid (8.8 mmol) was added 
trifluoroaceticanhydride (29.5 mmol) rapidly with 
 
 
Scheme I — Scheme for synthesis of 2, 2-dimethyl-2H-chromen-6-carbaldehyde 




vigorous stirring at 25°C. The mixture turned into a 
dark colored solution with vigorous exothermic 
reaction. The reaction mixture was stirred for 1 min at 
the same temperature and poured into ice cold water 
(50 ml) with stirring. Then it was washed with cold 
hexane (2×10 ml) to obtain desired ethanone 
derivatives as solid. 
To a solution of synthesized ethanone derivatives 
(200 mmol) in chloroform (30 ml) kept at 50°C was 
added dropwise bromine (220 mmol) with stirring. After 
being stirred at 50°C for 0.5 h, the mixture was washed 
successively with aqueous 10% sodium thiosulfate 
solution and water. The solvent was removed in vacuum 
to obtain the title compounds either as oil/solid 
mass/crystalline compounds (Scheme III). 
 
Procedure for synthesis of 2-(2,2-dimethyl-2H-
chromen-6-yl)-5-phenylimidazo[2,1-b][1,3,4]thiadiazole 
5-(2, 2-dimethyl-2H-chromen-6-yl)-1,3,4-thiadiazol-
2-amine(10 mmol) and 2-bromo-1-phenylethanone (10 
mmol) were added in RBF. This mixture is refluxed in 
dry ethanol (50 ml) for 15-18 hr. then resulting mixture 
was cooled at room temperature for 24 hr and excess 
solvent was removed at reduced pressure. The solid 
mass was washed by cold ethanol and also neutralized 
by cold aqueous solution of Na2CO3, so it gives the 
derivatives of thiadiazole (Scheme IV). 
 
Procedure for synthesis of 2-(2,2-dimethyl-2H-
chromen-6-yl)-5-(4-fluorophenyl)-6-(4-methoxyphenyl) 
imidazo [2, 1-b][1,3,4]thiadiazole 
5-(2,2-Dimethyl-2H-chromen-6-yl)-1,3,4-thiadiazol 
-2-amine (10 mmol) and 2-bromo-2-(4-fluorophenyl)-
 
 









Scheme IV — Scheme for synthesis of 2-(2,2-dimethyl-2H-
chromen-6-yl)-5-phenylimidazo[2,1-b][1,3,4]thiadiazole 




1-(4-methoxyphenyl)ethanone(10 mmol) were added 
in RBF. This mixture is refluxed in dry ethanol  
(50 ml) for 15-18 hr. then resulting mixture was 
cooled at room temperature for 24 hr and excess 
solvent was removed at reduced pressure. The solid 
mass was washed by cold ethanol and also neutralized 
by cold aqueous solution of Na2CO3, so it gives the 
thiadiazole derivatives 2-(2,2-dimethyl-2H-chromen-
6-yl)-5-(4-fluorophenyl)-6-(4-methoxyphenyl)imidazo 
[2,1-b][1,3,4]thiadiazole. It was recrystallised by dry 
ethanol (Scheme V). 
 
Anticancer screening by MTT (3-(4,5-dimethylthiazol 
-2-yl)-2,5-diphenyl tetrazolium bromide) assay44 
First to prepare MTT solution (stock solution) was 
5 mg in 1 ml of PBS (Phosphate Buffer Saline). The 
cell line used for the study was MCF-7. The MCF-7 
(Michigan Cancer Foundation-7) cell line was 
maintained in 96 wells microtiter plate containing 
MEM (Minimum Essential Medium) media 
supplemented with 10% heat inactivated fetal calf 
serum (FCS), containing 5% of mixture of 
Gentamicin (10ug), Penicillin (100 Units/ ml) and 
Streptomycin (100µg/ml) in presence of 5% CO2 
incubated at 37°C for 48-72 hours. In-vitro growth 
inhibition effect of test compound was assessed by 
calorimetric or spectrophotometric determination of 
conversion of MTT into “Formazan blue” by living 
cells. The MTT enters the cells and passes into the 
mitochondria where it is reduced to an insoluble, 
coloured (dark purple) formazan product. The cells 
are then solubilised with an organic solvent (eg. 
DMSO, Isopropanol) and the released, solubilised 
formazan reagent is measured spectrophotometrically. 
Since reduction of MTT can only occur in 
metabolically active cells the level of activity is a 
measure of the viability of the cells. So MTT assay 
performed by the remove the supernatant from the 
plate and add fresh MEM solution and treat with 
different concentrations of extract or compound 
appropriately diluted with DMSO. Control group 
contains only DMSO. In our study, 10, 20, 25, 30 and 
50 µl of the stock solution (10mg / ml prepared in 
DMSO) were added to respective wells containing 
100 µl of the medium. So, the final concentrations 
were 10, 20, 25, 30 and 50 µg / ml. After 48hrs 
incubation at 37ºC in a humidified atmosphere of 5% 
CO2, stock solution of MTT was added into each well 
(20µl, 5mg per ml in sterile PBS) for further 4 hrs 
incubation. The supernatant carefully aspirated, the 
 
 
Scheme V — Scheme for synthesis of 2-(2, 2-dimethyl-2H-chromen-6-yl)-5-(4-fluorophenyl)-6-(4-methoxyphenyl) imidazo 
[2, 1-b][1,3,4]thiadiazole 




precipitated crystals of “Formazan blue’ were 
solubilised by adding DMSO (100µl) and optical 
density was measured at wavelength of 570nm by 
using ELISA plus. The results represent the mean of 
five readings. The concentration in which the OD of 
treated cells was reduced by 50% with respect to the 
untreated control, it is known as IC50value.  
The % of Surviving cells which calculated by the 
formula that given below. 
 
Surviving cells (%) =  
                           Mean OD of test compound × 100 
                                Mean OD at control 
 
The % of Inhibition cells which calculated by the 
formula that given below. 
 
Inhibition cells (%) = 100 − Surviving cells (%) 
IC50 value was calculated by using graph pad 
software. In this software plot the graph of % 
inhibition vs. concentration and then software 





Biological activities of 2,2-dimethyl-2H-chromen 
derivatives were carried out on MCF-7 cancer cell 
line at Maratha College, Belgaum. The synthesized 
compound is 13 screened for the anticancer activity 
on MCF-7 cancer cell line. The resulting data is 




Physicochemical and spectral characterization 
During study, 2,2-dimethyl-2H-chromen containing 
derivatives were synthesized by conventional  
method. The synthesised 2,2-dimethyl-2H-chromen 
containing derivatives were characterized by the 
physicochemical properties and spectral data. The 
purity of 2,2-dimethyl-2H-chromen containing 
derivatives was confirmed by single spot TLC. 2,2-
dimethyl-2H-chromen containing derivatives were 
also confirmed by spectral data (FT-IR, Mss, 1H 
NMR). 
The FT-IR spectrum of the 4-hydroxybenzaldehyd 
(1) showed hydroxyl stretching vibrational bands at 
3194 cm-1 , strong carbonyl stretching vibrational 
band at 1667 cm-1 and bands around 3171 cm-1 
assigned to aromatic carbon-hydrogen single bond.  
The FT-IR spectrum of 2,2-dimethyl-2H-chromen-
6-carbaldehyde (4) showed strong carbonyl stretching 
vibrational band at 1665 cm-1, strong ether stretching 
vibrational band at 1399 cm-1 and bands around  
3168 cm-1 assigned to aromatic carbon-hydrogen 
single bond. 
The FT-IR spectrum of 2-(2,2-dimethyl-2H-
chromen -6-yl)-5-phenylimidazo[2,1-b][1,3,4-thiadiazole 
13 showed strong carbon-carbon stretching vibrational 
band at 1458 cm-1, strong ether stretching vibrational 
band at 1395 cm-1 , showed carbon-nitrogen stretching 
vibrational band at 1247 cm-1and bands around  




Figure 2 — Graph of % cell inhibition vs dose (µg/ml) for doxorubicin and 13 


















2 5 0.452 No lysis 
3 7.5 0.438 25% lysis 
4 10 0.358 50% lysis 









7 20 0.864 No lysis 
8 25 0.799 No lysis 
9 30 0.729 No lysis 
10 50 0.572 50 % lysis 
11 Control 1.131 - 




The mass spectrum of 2-(2,2-dimethyl-2H-
chromen-6-yl)-5-phenylimidazo[2,1-b][1,3,4-thiadiazole 
13 showed molecular ion peak (M+) at 359 m/e, based 
on molecular ion peak (M+) which confirmed the 
compound 13. 
In the 1H NMR spectrum of 2-(2,2-dimethyl-2H-
chromen-6-yl)-5-phenylimidazo[2,1-b][1,3,4-thiadiazole 
13 showed six proton of chromen C2 singlet at 1.232 
(d), one proton of chromen C3 multiplet at 6.774 - 
6.845 (d), six proton of chromen C4-6-7 and phenyl  
C10-11 multiplet at 7.274 – 7.862 (d),one proton of 
chromen C5 singlet at 8.356 (d), two proton of phenyl 
C9 and C13 multiplet at 8.556 – 8.682 (d),one proton 
of imidazo C6 singlet at 9.123 (d). 
 
Biological activity 
2,2-Dimethyl-2H-chromen containing final 
compound 13 was screened for anticancer activity  
on MCF-7 cancer cell line. During the course of  
study we observed that compound 13 showed 50% 
lysis of cancer cell. We observed that 2,2 dimethyl-
2H-chromen compound 13 showed IC50 value 50 
µg/ml. It was compared with standard drug 




The 2,2 dimethyl-2H-chromen derivatives was 
synthesized by using conventional method and then it 
was also confirmed by spectral data. 
The anticancer activities of synthesized compound 
13 were evaluated on MCF-7 cancer cell-line by MTT 
assay. We concluded that compound 13 has potent 
cytotoxicity with 50 µg/ml IC50 on MCF-7 cancer 
cell-line. Compound 13 is comparable with standard 
drug doxobubicin with IC50 10 µg/ml. So, we can 
conclude that the chromen containing derivative has 
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